Merz Pharmaceuticals GmbH Sustainability Profile
Merz Pharmaceuticals GmbH, a prominent player in the global healthcare landscape, is headquartered in Frankfurt, Germany. Founded in 1908, the company has established itself as a leader in the fields of aesthetics, neurology, and dermatology, with a strong presence across Europe, North America, and Asia. Merz is renowned for its innovative products, including the popular Belotero® and Xeomin® brands, which cater to the growing demand for non-surgical aesthetic treatments. The company’s commitment to research and development has led to significant advancements in therapeutic solutions, positioning it as a trusted name in the pharmaceutical industry. With a rich history and a focus on enhancing patient outcomes, Merz Pharmaceuticals continues to achieve notable milestones, solidifying its reputation as a pioneer in aesthetic and therapeutic medicine.
DitchCarbon Score
How does Merz Pharmaceuticals GmbH's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Merz Pharmaceuticals GmbH's score of 26 is lower than 51% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Merz Pharmaceuticals GmbH, headquartered in Germany (DE), currently does not have specific carbon emissions data available, as indicated by the absence of reported figures. The company is a current subsidiary of Merz Pharma GmbH & Co. KGaA, which may influence its climate commitments and emissions reporting. As of now, there are no documented reduction targets or climate pledges from Merz Pharmaceuticals GmbH. The lack of specific emissions data and reduction initiatives suggests that the company may still be in the early stages of formalising its climate strategy. Given the context of the pharmaceutical industry, it is essential for companies like Merz Pharmaceuticals to establish clear climate commitments and reduction targets to align with global sustainability goals. The absence of such data may reflect a broader trend within the sector, where many organisations are still developing comprehensive climate action plans. In summary, while Merz Pharmaceuticals GmbH does not currently report specific emissions or reduction targets, its affiliation with Merz Pharma GmbH & Co. KGaA may provide a framework for future climate initiatives.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2023 | 2024 | |
|---|---|---|
| Scope 1 | 2,088,000 | 0,000,000 |
| Scope 2 | 771,000 | 000,000 |
| Scope 3 | 36,782,000 | 00,000,000 |
How Carbon Intensive is Merz Pharmaceuticals GmbH's Industry?
How Carbon Intensive is Merz Pharmaceuticals GmbH's Location?
Merz Pharmaceuticals GmbH's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Merz Pharmaceuticals GmbH has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
